My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

40.81 +1.49 (+3.79%)

Official Closing Price Updated: 7:00 PM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner ↗

March 11, 2026

A new battle between these longtime rival companies will likely go the same way as their previous battles.

Via The Motley Fool

Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War

March 11, 2026

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant...

Via MarketMinute

The Greenland Ultimatum: Trump Weaponizes Tariffs in Bid for the Arctic's 'Crown Jewel'

March 11, 2026

The global trade landscape was thrown into a state of high-stakes volatility this quarter as President Trump issued a stark ultimatum to America’s closest European allies: enter negotiations for the...

Via MarketMinute

Topics Economy Electric Vehicles Government

The Dow’s Anchor: How UnitedHealth’s ‘Great Reset’ is Dragging Down the Blue-Chip Average

March 11, 2026

As of March 11, 2026, the Dow Jones Industrial Average is grappling with a heavyweight problem. UnitedHealth Group (NYSE: UNH), long the gold standard of the managed care sector and a primary engine of...

Via MarketMinute

Topics Stocks

Hims & Hers Health Stock Is Surging Wednesday: What's Going On? ↗

March 11, 2026

Hims & Hers Health Inc (NYSE: NVO) shares are higher Wednesday after a series of announcements this week reinforced investor optimism.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

March 10, 2026

From Pomerantz LLP

Via GlobeNewswire

The Great Biotech Divide: Vertex Soars on Multi-Franchise Breakthroughs as Novo Nordisk Stumbles in the Weight-Loss War

March 10, 2026

The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry...

Via MarketMinute

Novo Nordisk Sentiment Shifts as REDEFINE 4 Trial Results Trigger 16% Stock Plunge

March 10, 2026

The long-held dominance of Novo Nordisk (NYSE: NVO) in the global obesity market has been dealt a staggering blow following the release of the "worst-case scenario" results from the REDEFINE 4 Phase 3...

Via MarketMinute

Topics Government

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗

March 10, 2026

Via MarketBeat

Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗

March 10, 2026

As per the CEO, the company will have four late-stage trials by the end of 2026.

Via Stocktwits

2 Healthcare Stocks That Are Too Cheap to Ignore ↗

March 10, 2026

These companies' shares have fallen too far, offering investors an attractive opportunity.

Via The Motley Fool

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Topics Economy Intellectual Property Lawsuit

Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026

March 10, 2026

As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a...

Via Finterra

Topics Artificial Intelligence Economy

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗

March 10, 2026

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Via Stocktwits

Topics Intellectual Property Lawsuit

HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗

March 10, 2026

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners.

Via Stocktwits

Topics Intellectual Property Lawsuit

Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗

March 09, 2026

Hims & Hers stock traded more than 40% higher after the deal was announced.

Via The Motley Fool

Topics Lawsuit

Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock ↗

March 09, 2026

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

Via The Motley Fool

Hims & Hers Stock Pops 40%: Everything You Need to Know ↗

March 09, 2026

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

Via The Motley Fool

Topics Lawsuit

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗

March 09, 2026

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Via Stocktwits

Topics Intellectual Property Lawsuit

HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗

March 09, 2026

Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs.

Via Stocktwits

Topics Intellectual Property Lawsuit

Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗

March 08, 2026

They may appeal to different kinds of investors.

Via The Motley Fool

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

These companies have a lot more to offer than their prospects in the weight loss market.

Via The Motley Fool

Topics Intellectual Property

Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗

March 07, 2026

Things can't get that much worse for the drugmaker.

Via The Motley Fool

Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗

March 07, 2026

According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.

Via Stocktwits

Topics Initial Public Offering Intellectual Property Lawsuit

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? ↗

March 06, 2026

Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.

Via The Motley Fool

Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗

March 05, 2026

Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.

Via The Motley Fool

The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes

March 04, 2026

NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗

March 04, 2026

The notice comes weeks after a similar warning over Wegovy advertising, as the FDA ramps up scrutiny of marketing tied to GLP-1 drugs.

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

March 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

March 03, 2026

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.